Narrative review / 2013
Pharmacokinetic differences between oral and intravenous ascorbate warrant reassessing parenteral ascorbate as a cancer therapeutic.
This review evaluates the pharmacokinetic rationale for reassessing ascorbate in cancer treatment. Tight control of tissue and plasma levels limits oral ascorbate, whereas intravenous administration bypasses this control. High-dose ascorbate generates extracellular hydrogen peroxide and exhibits selective cytotoxicity in cell lines and murine xenografts. Although pilot clinical studies have verified the safety of intravenous ascorbate, questions regarding its clinical efficacy remain.
- Study type
- Narrative review
- Who was studied
- Cancer patients (historical trials and pilot studies)
- What was measured
- Ascorbate bioavailability, cytotoxicity, and cancer treatment efficacy
THE PAPER
Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics.
Parrow NL, Leshin JA, Levine M. Antioxid Redox Signal, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.